JPS6054284B2 - drug administration member - Google Patents

Description

DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a drug administration member, and more particularly to a transdermal administration member that can reliably absorb drugs longitudinally using a simple method.

When administering a drug by longitudinal absorption through the skin, it is difficult to administer the drug accurately and within a predetermined time due to the barrier function of the skin surface layer.

For this purpose, administration methods by longitudinal absorption include a method of incorporating a polar solvent into the base, a method of imparting heating or magnetic functions to an adhesive preparation, a compression method, a method of incorporating a pore expander into the base, and a method of adding a heating or magnetic function to an adhesive preparation. Although inoculation methods have been adopted, the current situation is that satisfactory results have not been obtained in terms of effectiveness, toxicity, usability, convenience, and storage stability.

In view of the state of the prior art, the inventors of the present invention conducted intensive research on a member that can administer drugs by simple and reliable longitudinal absorption, and as a result, they separated the drug-containing preparation from the member that removes the skin surface. The inventors have discovered that the above-mentioned problems can be solved by laminating as many layers as possible, leading to the present invention.

That is, in the present invention, an adhesive preparation having a pressure-sensitive adhesive base containing a drug on a carrier and a skin surface removal member having a pressure-sensitive adhesive layer on the carrier are separably laminated. Another object of the present invention is to provide a drug administration member characterized by the following.

- One embodiment of the present invention, as shown in FIG. 1, comprises an adhesive preparation A having a pressure-sensitive adhesive base 2 containing a drug on the surface of a carrier 1a, and a carrier lb. The pressure-sensitive adhesive surface of the skin removal member B having a pressure-sensitive adhesive layer 3 on its surface is separably laminated via a double-sided releasable film (or gate sheet) 4.

The second aspect of the present invention is that, as shown in FIG. 2, the formulation A is separably laminated on the back surface of the member B (the exposed surface of the carrier 1b) by temporarily adhering the adhesive layer 3 of the member B. A releasable film (or sheet) 4'' is temporarily attached to the surface.

In the third embodiment, as shown in FIG. 3, a releasable film (or sheet) 4'' is temporarily attached to the adhesive surfaces of the preparation A and the member B, and the carrier of the preparation A and the member B is 1a
and 1b are separably laminated on each other by adhesive means such as heat fusion or a binder such as rubber latex.

Various plastic films (
or sheet), nonwoven fabric, paper, cloth, etc., and the base 2
The adhesive material and the adhesive layer 3 are made of a synthetic resin and/or rubber that does not irritate the skin and has pressure-sensitive adhesive properties at room temperature. Each type of drug is used.

Adhesive layer 3 may contain an appropriate amount of a keratin softening agent that softens the skin surface or facilitates peeling and removal of the skin surface.

Examples of the auxiliary agent include polyhydric alcohols, fatty acid esters, and non-toxic organic solvents. Next, how to use the dosing member will be explained.

In the example shown in Fig. 1, member B-
is peeled off from the double-sided releasable film 4 and attached, and after a predetermined period of time, it is peeled off to remove the stratum corneum, and then the preparation A is attached. In the examples shown in FIGS. 2 and 3, the peelable film 4'' is peeled off to expose the adhesive layer 3, and the adhesive layer 3 is affixed to the application site as it is. After a predetermined time, it is peeled off.
and Preparation A are separated, and Preparation A is applied to the applied part via the base material 2 after the member B has been peeled off.

As described above, the drug administration member of the present invention comprises: Formulation A; Member B;
Since these are separably laminated, it is easy to remove the adhesive of component B to lower the barrier function of the skin surface layer and allow the drug to be absorbed transdermally. It has the characteristic that it is reliably absorbed through the skin because it is attached to the skin.

The present invention will be specifically described below using examples.

Example A blend of 10 parts by weight of natural rubber, 25 parts by weight of wood rosin, 5 parts by weight of polybutene (HV-300), 1 part by weight of polyethylene glycol and 3 parts by weight of an anti-aging agent was dissolved in toluene. , a 20% based adhesive material was prepared, and this was applied to one side of a 25.4 μm thick polyester film so that the thickness after drying was 100 pm. , cut to length Wd to make a skin surface removal member, and cut to width 5. ? , temporarily attached to the center of a 10.5 d long piece of double-sided releasable kraft paper.

On the other hand, isooctyl acrylate diacrylic acid = 96:
4 (weight ratio) was polymerized in ethyl acetate using benzoyl peroxide as a polymerization initiator to give a 25%
Make a base adhesive copolymer solution. 6 parts by weight of isosorbide dinitrate was mixed with 10 parts by weight of this solid content, and the mixture was coated and dried on the surface of a 12 μm thick polyester film so that the thickness after drying was 40 μm. A 5d1 length Wd is cut to make an adhesive preparation, and the adhesive preparation is pasted on the center of the surface of the above-mentioned kraft paper strip on the opposite side of the member to obtain the drug administration member of the present invention. Next, in order to evaluate the administration member, the skin surface removal member was first peeled off from the kraft paper piece, adhered to the lower arm of a human body, and then crimped, and peeled off after one peel. After this peeling, the preparation was peeled off from a piece of kraft paper and pasted, and 3 hours later, blood was collected and the blood concentration was measured using a conventional method. The effective blood concentration of dodinitrate is 2-4ny1n1). For comparison, the blood concentration measured 3 hours after applying only the preparation directly to the lower arm was 1.1n'1ml.

In addition, the pharmacological effects were such that some skin irritation and mild headache were observed.

[Brief explanation of the drawing]

1 to 3 are side views showing examples of the present invention. A: Adhesive preparation, B: Skin surface removal member.

Claims (1)

[Scope of Claims] 1. An adhesive preparation having a pressure-sensitive adhesive base containing a drug on a carrier and a skin surface removal member having a pressure-sensitive adhesive layer on the carrier are separably laminated. A drug administration member characterized in that: 2. The drug administration member according to claim 1, wherein the pressure-sensitive adhesive surfaces of the adhesive preparation and the skin surface removal member are separably laminated via a peelable film (or sheet). 3. The drug administration member according to claim 1, wherein the adhesive preparation is separably laminated on the back surface of the skin surface removal member. 4. The drug administration member according to claim 1, wherein the adhesive preparation and the skin surface removal member are laminated so that their back surfaces can be separated from each other. 5. In the drug administration member according to any one of claims 1 to 4, a keratin softening agent is blended into the pressure-sensitive adhesive layer constituting the skin surface removal member.